X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria.
Invitae, San Francisco, CA, United States.
Front Immunol. 2024 Jul 8;15:1411141. doi: 10.3389/fimmu.2024.1411141. eCollection 2024.
Warts, Hypogammaglobulinemia, Infections, Myelokathexis (WHIM) syndrome is a rare, combined immunodeficiency disease predominantly caused by gain-of-function variants in the gene that typically results in truncation of the carboxyl terminus of C-X-C chemokine receptor type 4 (CXCR4) leading to impaired leukocyte egress from bone marrow to peripheral blood. Diagnosis of WHIM syndrome continues to be challenging and is often made through clinical observations and/or genetic testing. Detection of a pathogenic variant in an affected individual supports the diagnosis of WHIM syndrome but relies on an appropriate annotation of disease-causing variants. Understanding the genotypic-phenotypic associations in WHIM syndrome has the potential to improve time to diagnosis and guide appropriate clinical management, resulting in a true example of precision medicine. This article provides an overview of the spectrum of variants in WHIM syndrome and summarizes the various lines of clinical and functional evidence that can support interpretation of newly identified variants.
疣、低丙种球蛋白血症、感染、骨髓嗜中性粒细胞减少(WHIM)综合征是一种罕见的联合免疫缺陷病,主要由 基因的功能获得性变异引起,通常导致 C-X-C 趋化因子受体 4(CXCR4)羧基末端截断,导致白细胞从骨髓外溢到外周血减少。WHIM 综合征的诊断仍然具有挑战性,通常通过临床观察和/或基因检测来做出。在受影响的个体中检测到致病性 变异可支持 WHIM 综合征的诊断,但依赖于对致病变异的适当注释。了解 WHIM 综合征的基因型-表型相关性有可能提高诊断时间并指导适当的临床管理,从而真正实现精准医学。本文概述了 WHIM 综合征中 变异的范围,并总结了各种临床和功能证据,这些证据可以支持对新鉴定的变异的解释。